Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 6Recruiting 3Unknown 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma 1

Interventions

Drug Therapy 107Cisplatin 97Radiotherapy 89Carboplatin 87Bevacizumab 79Oxaliplatin 74tislelizumab 68Capecitabine 67Cyclophosphamide 65Gemcitabine 64toripalimab 61Paclitaxel 57Specimen Handling 55pembrolizumab 54sintilimab 53Surgical Procedures, Operative 52anlotinib 49Magnetic Resonance Spectroscopy 49Fluorouracil 49Immune Checkpoint Inhibitors 43Blood Specimen Collection 42130-nm albumin-bound paclitaxel 42Standard of Care 39camrelizumab 36fludarabine 35lenvatinib 34Leucovorin 34venetoclax 30Radiosurgery 30Immunotherapy 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × OTHER × Sulfasalazine × Clear all
NCT06557330 2025-01-06

MRD Guided De-intensification of Bendamustine/Rituximab for Indolent Non-Hodgkin Lymphoma

Fox Chase Cancer Center

Phase 2 Not yet recruiting
24 enrolled
Lymphoid

Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡